BIDMC investigator Mary Bouxsein helped secure FDA approval of bone density imaging as a faster endpoint for osteoporosis ...

The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.

Millions of osteoporosis patients worldwide are set to benefit from a major international breakthrough, which will transform ...

(MENAFN- EIN Presswire) EINPresswire/ -- Osteoporosis Drugs Market to Surpass $16 billion in 2029. In comparison, the Drugs For Rheumatoid Arthritis market, which is considered as its parent market, ...

Although there are several effective anti-osteoporosis drugs on the market today, new therapies with improved safety profiles and efficacy are still needed. The FDA called osteoporosis-related ...

A new international study published in Osteoporosis International and led by Monash's Center for Medicine Use and Safety (CMUS) has investigated the risks of a second hip fracture, subsequent ...

Boston-based Beth Israel Deaconess Medical Center played a role in a new FDA decision that allows bone mineral density, measured through noninvasive imaging, to serve as a qualified endpoint in ...

For decades, osteoporosis has meant a slow, one way slide toward fragile bones and fracture risk, managed but rarely truly ...

A healthy gut may be far more important for women’s bone health than previously believed. New research conducted by AIIMS has ...

Researchers have shown that glioblastoma can take over the skull marrow to dissolve bone and feed its own growth, suggesting ...

Eliminating senescent brain cells in animal models showed seizure reduction and cognitive improvement potential.